Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,EDIT,637996000.0,67826400,,,-56728000,,-56728000,21445000,-35438000,-56883000,-56883000,,,,,,0,6499000,63382000,41937000,155000,,-56728000,-56728000,1359987000.0,142298000.0,637996000.0,33117000.0,780294000.0,7000.0,-721925000.0,56667000.0,-73000.0,6688000.0,354918000.0,64010000.0,-73000.0,43400000.0,632316000.0,97890000.0,270415000.0,672000.0,8910000.0,3328000,-3538000,3244000,261471000,-8357000,261471000,215236000,-49479000,1163000,5376000,12605000,-84000,568306000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,66.6,1630507519,3.0099983,63.75,66.73,63.13,495931,"Editas Medicine, Inc.",NMS,REGULAR,0.52236384,0,False,False,4.7334456,63.13 - 66.73,63.59,65.53,65.7,8,10,finmb_252050056,NasdaqGS,"Editas Medicine, Inc.",USD,1933232,1517050,39.589996,1.4657533,27.01 - 99.95,-33.35,-0.33366683,27.01,99.95,1620217800,1636023540,1636459200,-2.196,-3.74,2,-3.47,-19.193083,9.456,52.076668,14.523331,0.27888364,43.747753,22.852245,4517238272,-17.807486,7.0431466,15,America/New_York,EDT,-14400000,1.93,,,99.95,27.01,52.08,43.75,1.93M,1.52M,67.83M,,66.83M,0.25%,75.79%,10.37M,10.05,17.99%,15.29%,10.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-147.51%,-158.57%,-14.54%,-30.94%,91.51M,1.49,13.60%,-67.26M,-140.78M,-134.98M,-2.20,,625.33M,9.23,28.89M,4.53,9.88,9.46,-175.24M,-65.67M,Value,02141,Healthcare,235,7,2,"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 401 9000,MA,9,1609372800,1625011200,9,United States,http://www.editasmedicine.com,86400,9,11 Hurley Street,617 494 0985,Biotechnology
t-1,EDIT,393586000.0,67826400,,,-62499000,,-62499000,15787000,-50085000,-65872000,-65872000,,,,,,0,11419000,77291000,61504000,3373000,,-62499000,-62499000,1058823000.0,179016000.0,393586000.0,21714000.0,572602000.0,6000.0,-665197000.0,101484000.0,-46000.0,4703000.0,139682000.0,58208000.0,-46000.0,39148000.0,419087000.0,109664000.0,262428000.0,6048000.0,6408000.0,-107509000,-4466000,-108894000,9100000,370000,9100000,-139894000,-40100000,1183000,-4993000,30305000,-1376000,360879000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,66.6,1630507519,3.0099983,63.75,66.73,63.13,495931,"Editas Medicine, Inc.",NMS,REGULAR,0.52236384,0,False,False,4.7334456,63.13 - 66.73,63.59,65.53,65.7,8,10,finmb_252050056,NasdaqGS,"Editas Medicine, Inc.",USD,1933232,1517050,39.589996,1.4657533,27.01 - 99.95,-33.35,-0.33366683,27.01,99.95,1620217800,1636023540,1636459200,-2.196,-3.74,2,-3.47,-19.193083,9.456,52.076668,14.523331,0.27888364,43.747753,22.852245,4517238272,-17.807486,7.0431466,15,America/New_York,EDT,-14400000,1.93,,,99.95,27.01,52.08,43.75,1.93M,1.52M,67.83M,,66.83M,0.25%,75.79%,10.37M,10.05,17.99%,15.29%,10.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-147.51%,-158.57%,-14.54%,-30.94%,91.51M,1.49,13.60%,-67.26M,-140.78M,-134.98M,-2.20,,625.33M,9.23,28.89M,4.53,9.88,9.46,-175.24M,-65.67M,Value,02141,Healthcare,235,7,2,"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 401 9000,MA,9,1609372800,1625011200,9,United States,http://www.editasmedicine.com,86400,9,11 Hurley Street,617 494 0985,Biotechnology
t-2,EDIT,441152000.0,67826400,,,7819000,,7819000,19936000,28925000,8989000,8989000,,,,,,0,62841000,53852000,33916000,-1170000,,7819000,7819000,1043892000.0,156005000.0,441152000.0,23009000.0,597157000.0,6000.0,-602698000.0,80821000.0,-48000.0,3877000.0,279576000.0,54816000.0,-48000.0,40467000.0,506827000.0,45986000.0,215729000.0,1055000.0,5158000.0,-150479000,-80124000,-152265000,822000,8321000,822000,-206244000,-54801000,1107000,810000,7266000,-1793000,452011000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,66.6,1630507519,3.0099983,63.75,66.73,63.13,495931,"Editas Medicine, Inc.",NMS,REGULAR,0.52236384,0,False,False,4.7334456,63.13 - 66.73,63.59,65.53,65.7,8,10,finmb_252050056,NasdaqGS,"Editas Medicine, Inc.",USD,1933232,1517050,39.589996,1.4657533,27.01 - 99.95,-33.35,-0.33366683,27.01,99.95,1620217800,1636023540,1636459200,-2.196,-3.74,2,-3.47,-19.193083,9.456,52.076668,14.523331,0.27888364,43.747753,22.852245,4517238272,-17.807486,7.0431466,15,America/New_York,EDT,-14400000,1.93,,,99.95,27.01,52.08,43.75,1.93M,1.52M,67.83M,,66.83M,0.25%,75.79%,10.37M,10.05,17.99%,15.29%,10.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-147.51%,-158.57%,-14.54%,-30.94%,91.51M,1.49,13.60%,-67.26M,-140.78M,-134.98M,-2.20,,625.33M,9.23,28.89M,4.53,9.88,9.46,-175.24M,-65.67M,Value,02141,Healthcare,235,7,2,"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 401 9000,MA,9,1609372800,1625011200,9,United States,http://www.editasmedicine.com,86400,9,11 Hurley Street,617 494 0985,Biotechnology
t-3,EDIT,426772000.0,67826400,,,-23572000,,-23572000,14081000,-17258000,-31339000,-31339000,,,,,,0,10749000,42088000,28007000,7767000,,-23572000,-23572000,1037100000.0,228709000.0,426772000.0,45780000.0,655481000.0,6000.0,-610517000.0,138406000.0,183000.0,3891000.0,485819000.0,68150000.0,183000.0,41464000.0,610126000.0,,112901000.0,1865000.0,6339000.0,76000000,-6807000,74173000,211153000,534000,211153000,254470000,-30856000,871000,-33000,-1849000,-1841000,541976000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,66.6,1630507519,3.0099983,63.75,66.73,63.13,495931,"Editas Medicine, Inc.",NMS,REGULAR,0.52236384,0,False,False,4.7334456,63.13 - 66.73,63.59,65.53,65.7,8,10,finmb_252050056,NasdaqGS,"Editas Medicine, Inc.",USD,1933232,1517050,39.589996,1.4657533,27.01 - 99.95,-33.35,-0.33366683,27.01,99.95,1620217800,1636023540,1636459200,-2.196,-3.74,2,-3.47,-19.193083,9.456,52.076668,14.523331,0.27888364,43.747753,22.852245,4517238272,-17.807486,7.0431466,15,America/New_York,EDT,-14400000,1.93,,,99.95,27.01,52.08,43.75,1.93M,1.52M,67.83M,,66.83M,0.25%,75.79%,10.37M,10.05,17.99%,15.29%,10.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-147.51%,-158.57%,-14.54%,-30.94%,91.51M,1.49,13.60%,-67.26M,-140.78M,-134.98M,-2.20,,625.33M,9.23,28.89M,4.53,9.88,9.46,-175.24M,-65.67M,Value,02141,Healthcare,235,7,2,"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 401 9000,MA,9,1609372800,1625011200,9,United States,http://www.editasmedicine.com,86400,9,11 Hurley Street,617 494 0985,Biotechnology
